150 related articles for article (PubMed ID: 7563904)
1. [Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b].
Sakuma I; Enomoto N; Asahina Y; Kurosaki M; Sato C
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):930-5. PubMed ID: 7563904
[No Abstract] [Full Text] [Related]
2. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
[TBL] [Abstract][Full Text] [Related]
3. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
Herion D; Hoofnagle JH
Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
[No Abstract] [Full Text] [Related]
4. [Genomic changes in the E2/NS1 region of HCV before and after IFN therapy].
Higashi Y; Kakumu S
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):923-9. PubMed ID: 7563902
[No Abstract] [Full Text] [Related]
5. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
Zeuzem S; Lee JH; Roth WK
Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
[TBL] [Abstract][Full Text] [Related]
6. Novel interferons for treatment of hepatitis C virus.
Clark V; Nelson DR
Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of hepatitis C virus quasispecies.
Enomoto N; Sato C
J Viral Hepat; 1995; 2(6):267-72. PubMed ID: 8732171
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.
Torres-Puente M; Cuevas JM; Jiménez-Hernández N; Bracho MA; García-Robles I; Carnicer F; del Olmo J; Ortega E; Moya A; González-Candelas F
J Med Virol; 2008 Feb; 80(2):247-53. PubMed ID: 18098147
[TBL] [Abstract][Full Text] [Related]
9. [Fluctuation of HCV quasi-species population during interferon therapy; analysis by single strand conformation polymorphism].
Enomoto N; Kurosaki M; Koizumi K; Asahina Y; Sakuma I; Murakami T; Yamamoto C; Marumo F; Sato C
Nihon Rinsho; 1994 Jul; 52(7):1707-15. PubMed ID: 7521408
[TBL] [Abstract][Full Text] [Related]
10. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
Shedlofsky SI
Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
[No Abstract] [Full Text] [Related]
11. [Prediction of interferon therapy outcome by PCR-SSCP analysis of HCV 5' NCR].
Kurihara C; Katayama K; Fukushi S; Hoshino FB; Ando T; Oya A; Ishiyama N
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):326-32. PubMed ID: 7563742
[No Abstract] [Full Text] [Related]
12. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy.
Nishiguchi S; Ueda T; Itoh T; Enomoto M; Tanaka M; Tatsumi N; Fukuda K; Tamori A; Habu D; Takeda T; Otani S; Shiomi S
Hepatology; 2001 Jan; 33(1):241-7. PubMed ID: 11124842
[TBL] [Abstract][Full Text] [Related]
13. Future therapies for hepatitis C.
Pawlotsky JM; Gish RG
Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
[TBL] [Abstract][Full Text] [Related]
14. [HCV-serotype and IFN response].
Abe K; Miyakawa H; Kako M; Horikoshi K
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):959-64. PubMed ID: 7563910
[No Abstract] [Full Text] [Related]
15. [Change of HCV-RNA levels in liver tissue and interferon responsiveness in patients with chronic hepatitis C].
Takeuchi M; Kaneko S; Unoura M; Kobayashi K
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):969-74. PubMed ID: 7563912
[No Abstract] [Full Text] [Related]
16. Heterogeneity in E2 region of GBV-C/hepatitis G virus and hepatitis C virus.
Kato T; Mizokami M; Nakano T; Orito E; Ohba K; Kondo Y; Tanaka Y; Ueda R; Mukaide M; Fujita K; Yasuda K; Iino S
J Med Virol; 1998 Jun; 55(2):109-17. PubMed ID: 9598930
[TBL] [Abstract][Full Text] [Related]
17. The molecular basis for responsiveness to anti-viral therapy in hepatitis C.
Polyak SJ; Gerotto M
Forum (Genova); 2000; 10(1):46-58. PubMed ID: 10717257
[TBL] [Abstract][Full Text] [Related]
18. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
Feld JJ; Hoofnagle JH
Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
[TBL] [Abstract][Full Text] [Related]
20. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
Gervain J; Czibula A; Simon J; Kalmár T
Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
